Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Bioalliance Pharma Announces Its Participation in the Natixis Securities Midcap Healthcare Conference

Abstract:
BioAlliance Pharma SA (Paris:BIO), a specialty pharmaceutical company focused on the development and marketing of innovative therapeutics which address resistance issues in cancer, HIV and opportunistic infections, today announced that it will take part in an international business conference devoted to meetings between institutional investors and healthcare/biotech companies:

* The Natixis Securities MidCap Healthcare Conference, November 16, Paris.

(at Salons France Amériques, 9-11 Avenue Franklin Roosevelt)

Dominique Costantini, BioAlliance Pharma's President and CEO, will present the company to institutional investors in plenary session #1 at 9.45am on Friday, November 16.

Bioalliance Pharma Announces Its Participation in the Natixis Securities Midcap Healthcare Conference

PARIS, France | Posted on November 12th, 2007

BioAlliance is the first French high-growth company to have developed a product on the basis of innovative academic research results and to have completed the drug development process all the way up to and including market launch. With a broad and diversified portfolio of innovative products (including three in Phase III trials and a number of promising preclinical programs in cancer and HIV), the company has highlighted its determination to achieve growth throughout Europe.

####

About BioAlliance Pharma SA
BioAlliance Pharma SA (Euronext Paris: BIO) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics targeting cancer, HIV, opportunistic infections and drug resistance. The company is currently developing three innovative clinical-phase products based on the Lauriad® muco-adhesive technology (which enables early, prolonged release of therapeutic agents at the site of the disease; one product is already on the market in France and two phase III clinical trials are ongoing - Loramyc® and acyclovir Lauriad®) and the Transdrug® nanoparticle technology (designed specifically for intracellular targeting of resistant cells: a pivotal phase III primary liver cancer trial is underway with doxorubicin Transdrug®). The company is also developing a new therapeutic entities program focused on the oncology and HIV market.

In 2007, the company established two strategic partnerships to sell its first product (Loramyc®) in the USA and Europe (where the French market launch was announced in September 2007).

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 6th 2007 under the number R. 07-031, which is available on the AMF website ( http://www.amf-france.org ) or on BioAlliance Pharma S.A.'s website ( http://www.bioalliancepharma.com ).

For press releases and other company information, visit http://www.bioalliancepharma.com .

For more information, please click here

Contacts:
BioAlliance Pharma SA
Dominique Costantini
President and CEO
Tel.: +33 1 45 58 76 01

or
Nicolas Fellmann
CFO
Tel.: +33 1 45 58 71 00

or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59

Copyright © Business Wire 2007

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Untangling DNA: Researchers filter the entropy out of nanopore measurements December 8th, 2017

Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy — Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 — December 6th, 2017

Announcements

A new product to help combat mouldy walls, thanks to technology developed at the ICN2 December 14th, 2017

Sandia researchers make solid ground toward better lithium-ion battery interfaces: Reducing the traffic jam in batteries December 13th, 2017

Perking up and crimping the 'bristles' of polyelectrolyte brushes December 13th, 2017

Columbia engineers create artificial graphene in a nanofabricated semiconductor structure: Researchers are the first to observe the electronic structure of graphene in an engineered semiconductor; finding could lead to progress in advanced optoelectronics and data processing December 13th, 2017

Events/Classes

Leti to Demo Wristband with Embedded Sensors to Diagnose Sleep Apnea: APNEAband, Which Will Be Demonstrated at CES 2018, Also Monitors Mountain Sickness, Dehydration, Dialysis Treatment Response and Epileptic Seizures December 12th, 2017

Arrowhead Presents New Clinical Data Demonstrating a Sustained Host Response in Hepatitis B Patients Following RNAi Therapy — Up to 5.0 log10 reduction in HBsAg observed; data presented at HEP DART 2017 — December 6th, 2017

Leti Breakthroughs Point Way to Significant Improvements in SoC Memories December 6th, 2017

NanoSummit in Luxembourg: single wall carbon nanotubes have entered our lives as we approach a nanoaugmented future November 23rd, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project